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Abstract
New potent vaccine adjuvants are desirable for increasing the efficacy of novel vaccine modalities
such as DNA and peptides. We therefore tested if syngeneic erythrocytes could serve as delivery
vectors for selected HIV peptides and compared the potency of these constructs to immunization
with peptides in phosphate buffered saline or in incomplete Freunds adjuvant.
Immunization of mice with peptides in a low dose (5 ng) coupled to erythrocytes induced a weak
immune response in mice. These peptides alone (5 μg) gave no immune responses, while
formulating the peptides (50 μg) in IFA induced strong homologous immunity as well as prominent
cross reactivity to a related mutant epitope. Thus, vaccine delivery using syngeneic erythrocytes,
although attractive for clinical use, might be of limited value due to the low amount of antigen that
can be loaded per erythrocyte.
Findings
Peptide-based vaccines have been shown to be immuno-
genic in animal models, and well tolerated in man [1,2].
One major benefit of peptide-based immunogens is the
ease with which the vaccine can be modulated in order to
fit new variants of a variable microbe such as HIV [3]. One
application of such a vaccine strategy would be to target
viral mutants conferring escape from antiretroviral drugs.
As certain known mutations within epitopes of the HIV
proteins are associated with resistance to the drugs [4]
those epitopes variants could be included in a peptide-
based vaccine. However these kinds of vaccines may need
to be adjuvanted in order to be used in humans. The strat-
egy of using syngeneic erythrocytes as delivery vectors is
attractive, since no external compounds are used. Further,
red blood cells (RBCs) are naturally removed by macro-
phages from the bloodstream and thereby targeted to
immune cells. In addition, no toxic side effects have been
found in host tissue following RBC-antigen delivery [5].
HIV Tat protein coupled to red blood cells was shown to
induce as potent immune response as protein formulated
in Freund's adjuvant [6]. The RBC method also induced
protective immunity in mice and cats lethally challenged
with HSV-1 and FIV-M2, respectively [7,8]. The objective
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of the present study was to test the efficacy of syngeneic
erythrocytes as delivery vectors and adjuvant for peptides
deriving from the HIV-1 protease.
A human leukocyte antigen (HLA) A0201 restricted
epitope, deriving from HIV-1 protease (PR75–84 wt, VLVGP-
TPVNI) and a mutant variant (PR75–84 d.mut) harboring two
drug resistance mutations, V82F and I84V were resus-
pended in phosphate buffered saline (PBS), biotinylated
and coupled to syngeneic erythrocytes by avidin-biotin
bridges [5,9-12]. The amount of peptide bound to the red
blood cells was estimated to 25 ng/mL blood [7,9]. Solu-
ble peptides were formulated in PBS or in incomplete Fre-
unds adjuvant (IFA) to a final concentration of 1 mg/ml.
The peptide/IFA mixtures were sonicated (Sonica Vibra
Cell VC100, Kenosia Ave, US) at a constant output of 40%
for ~30–60 s on ice and the emulsions were used for
immunization. C57Bl/6 mice, transgenic for the HLA-
A0201 allele, were immunized according to Table 1. The
animals were bled 10–12 days following each immuniza-
tion and three mice per group were sacrificed 10 weeks
after the last injection. IFN-γ ELISpot (Mabtech, Nacka,
Sweden) was used for readout of cellular immunity. The
plates were read by the AID ELISpot reader system. Statis-
tical analysis was performed using GraphPad Prism 4.0.
The nonparametric Kruskal-Wallis test was used to iden-
tify differences among the different groups, and Mann-
Whitney U test was used for post hoc pair-wise compari-
sons.
A strong immune response was detected in blood against
the individual peptides PR75–84 wt and PR75–84 d.mut follow-
ing peptide/IFA-immunizations, Figures 1A and 1B. This
response culminated 2 weeks after the second immuniza-
tion and 10 weeks after the last injection the response was
similar to that seen at week 7, Figures 1A and 1B. Of par-
ticular interest is, that immunization with either wild type
or mutant epitope induced both high responses to the
homologous peptide but also prominent cross-recogni-
tion to a related mutant peptide. Ten weeks after the last
injection a response to both of the epitope variants could
be seen in spleens from the PR75–84 wt immunized group,
Figures 1C and 1D. The mice, in which RBC was used for
peptide delivery showed, after repeated immunization
with the RBC-HIV peptide conjugates (5–12,5 ng/injec-
tion), only a weak response in spleen cells, Figures 1C and
1D. This response was however significantly stronger (p =
0.0238) than that in mice immunized three times with a
five hundred-fold higher concentration of soluble peptide
(5 μg) formulated in PBS, Figures 1C and 1D.
We have previously shown that peptide immunization
with the wild type protease epitope, PR75–84 wt, or the
mutant variant, PR75–84 d.mut, both formulated in IFA,
induces potent immune responses in mice [13]. This sug-
gests that choosing either of these peptides as a compo-
nent in a vaccine may suppress wild type virus as well as
viral variants carrying drug-induced mutations [13]. Based
on these findings we compared delivery of the two HIV
protease peptides, PR75–84 wt and PR75–84 d.mut, either pre-
pared in emulsion with IFA or coupled to syngeneic eryth-
rocytes. To further increase the uptake of the peptide/
erythrocyte complex by antigen presenting cells, the eryth-
rocytes were chemically modified to be recognized as
aging by macrophages and thereby cleared more rapidly
by macrophages and antigen-presenting cells [5,10]. A
strong immune response was detected after peptide/IFA
immunization, whereas only a weak cellular response was
measurable upon four consecutive RBC-peptide conjugate
immunization. In a parallel experiment, 5 μg of PR75–84
d.mut peptide in PBS was used for immunization and this
amount of peptide without adjuvant did not induce any
immune responses. These findings suggest that erythro-
cytes may serve as delivery vectors for very small amounts
of peptide. Since the loading capacity of erythrocytes is
limited, as well as the volume of blood for each injection,
the enhanced presentation of peptides to macrophages by
the modified erythrocytes is probably not sufficient to
compensate for a small amount of peptide antigen in a
clinical scenario.
Table 1: Immunization schedule of the study
Groups Adjuvant/Carrier1 Immunogens Amounts Site of injection1 Symbol used in Figure 1
PR75–84 wt IFA VLVGPTPVNI 4 × 50 μgs . c Downward pointing triangle
PR75–84 d.mut IFA VLVGPTPFNV 4 × 50 μgs . c Black filled Diamond
PR75–84 d.mut low2 - VLVGPTPFNV 4 × 5 μgs . c Blue open Diamond
RBC-PR75–84 wt RBC VLVGPTPVNI biotinylated to 
synergeneic erythrocytes
2 × 5 ng3 + 2 × 12.5 ng4 i.p Square
RBC-PR75–84 d.mut RBC VLVGPTPFNV biotinylated to 
syngeneic erythrocytes
2 × 5 ng3 + 2 × 12.5 ng4 i.p Triangle
RBCempty RBC Biotinylated syngeneic erythrocytes 3 × 200 μl + 1 × 500 μl blood i.p Circle
Untreated - - - - Cross
1 IFA = Incomplete Freunds adjuvant; RBC = Red blood cell; s.c = subcutaneous; i.p = intraperitoneal
2A parallel study
3 Corresponds to 200 μl blood
4 Corresponds to 500 μl bloodInfectious Agents and Cancer 2007, 2:9 http://www.infectagentscancer.com/content/2/1/9
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